323 related articles for article (PubMed ID: 10910081)
1. Cadherin switching in human prostate cancer progression.
Tomita K; van Bokhoven A; van Leenders GJ; Ruijter ET; Jansen CF; Bussemakers MJ; Schalken JA
Cancer Res; 2000 Jul; 60(13):3650-4. PubMed ID: 10910081
[TBL] [Abstract][Full Text] [Related]
2. Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells.
Morton RA; Ewing CM; Nagafuchi A; Tsukita S; Isaacs WB
Cancer Res; 1993 Aug; 53(15):3585-90. PubMed ID: 8339265
[TBL] [Abstract][Full Text] [Related]
3. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer.
Umbas R; Schalken JA; Aalders TW; Carter BS; Karthaus HF; Schaafsma HE; Debruyne FM; Isaacs WB
Cancer Res; 1992 Sep; 52(18):5104-9. PubMed ID: 1516067
[TBL] [Abstract][Full Text] [Related]
4. Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E-cadherin function.
Ewing CM; Ru N; Morton RA; Robinson JC; Wheelock MJ; Johnson KR; Barrett JC; Isaacs WB
Cancer Res; 1995 Nov; 55(21):4813-7. PubMed ID: 7585512
[TBL] [Abstract][Full Text] [Related]
5. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression of E-cadherin in the progression of rat prostatic cancer.
Bussemakers MJ; van Moorselaar RJ; Giroldi LA; Ichikawa T; Isaacs JT; Takeichi M; Debruyne FM; Schalken JA
Cancer Res; 1992 May; 52(10):2916-22. PubMed ID: 1581909
[TBL] [Abstract][Full Text] [Related]
7. N-cadherin switching occurs in high Gleason grade prostate cancer.
Jaggi M; Nazemi T; Abrahams NA; Baker JJ; Galich A; Smith LM; Balaji KC
Prostate; 2006 Feb; 66(2):193-9. PubMed ID: 16173043
[TBL] [Abstract][Full Text] [Related]
8. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival.
Richmond PJ; Karayiannakis AJ; Nagafuchi A; Kaisary AV; Pignatelli M
Cancer Res; 1997 Aug; 57(15):3189-93. PubMed ID: 9242448
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of E-cadherin and ezrin immunohistochemical expression in prostate cancer.
Musiał J; Sporny S; Nowicki A
Pol J Pathol; 2007; 58(4):235-43. PubMed ID: 18459457
[TBL] [Abstract][Full Text] [Related]
10. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer.
Umbas R; Isaacs WB; Bringuier PP; Schaafsma HE; Karthaus HF; Oosterhof GO; Debruyne FM; Schalken JA
Cancer Res; 1994 Jul; 54(14):3929-33. PubMed ID: 7518346
[TBL] [Abstract][Full Text] [Related]
11. Pan-cadherin as a high level phenotypic biomarker for prostate cancer.
Wehbi NK; Dugger AL; Bonner RB; Pitha JV; Hurst RE; Hemstreet GP
J Urol; 2002 May; 167(5):2215-21. PubMed ID: 11956481
[TBL] [Abstract][Full Text] [Related]
12. The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer.
Contreras HR; Ledezma RA; Vergara J; Cifuentes F; Barra C; Cabello P; Gallegos I; Morales B; Huidobro C; Castellón EA
Urol Oncol; 2010; 28(5):534-40. PubMed ID: 19450993
[TBL] [Abstract][Full Text] [Related]
13. Altered localization of E-cadherin and alpha-catenin in rat esophageal tumors.
Khare L; Sabourin CL; De Young BR; Jamasbi RJ; Stoner GD
Int J Oncol; 1999 Jan; 14(1):33-40. PubMed ID: 9863006
[TBL] [Abstract][Full Text] [Related]
14. P-Cadherin is a basal cell-specific epithelial marker that is not expressed in prostate cancer.
Jarrard DF; Paul R; van Bokhoven A; Nguyen SH; Bova GS; Wheelock MJ; Johnson KR; Schalken J; Bussemakers M; Isaacs WB
Clin Cancer Res; 1997 Nov; 3(11):2121-8. PubMed ID: 9815605
[TBL] [Abstract][Full Text] [Related]
15. Cadherin-11 is expressed in invasive breast cancer cell lines.
Pishvaian MJ; Feltes CM; Thompson P; Bussemakers MJ; Schalken JA; Byers SW
Cancer Res; 1999 Feb; 59(4):947-52. PubMed ID: 10029089
[TBL] [Abstract][Full Text] [Related]
16. Expression of E-cadherin, P-cadherin and N-cadherin in oral squamous cell carcinoma: correlation with the clinicopathologic features and patient outcome.
Pyo SW; Hashimoto M; Kim YS; Kim CH; Lee SH; Johnson KR; Wheelock MJ; Park JU
J Craniomaxillofac Surg; 2007 Jan; 35(1):1-9. PubMed ID: 17296306
[TBL] [Abstract][Full Text] [Related]
17. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
Zhang H; Stephens LC; Kumar R
Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
[TBL] [Abstract][Full Text] [Related]
18. The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer.
Yoshida R; Kimura N; Harada Y; Ohuchi N
Int J Oncol; 2001 Mar; 18(3):513-20. PubMed ID: 11179480
[TBL] [Abstract][Full Text] [Related]
19. E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions.
Davidson B; Berner A; Nesland JM; Risberg B; Berner HS; Tropè CG; Kristensen GB; Bryne M; Ann Florenes V
J Pathol; 2000 Dec; 192(4):460-9. PubMed ID: 11113863
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of E-cadherin and beta-catenin proteins in metastatic prostate cancer cells in bone.
Saha B; Arase A; Imam SS; Tsao-Wei D; Naritoku WY; Groshen S; Jones LW; Imam SA
Prostate; 2008 Jan; 68(1):78-84. PubMed ID: 18008331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
